#6 - Medtronic (NYSE:MDT)
Medtronic PLC (NYSE: MDT) is one of the world's leading medical device companies. Like many companies in this niche, MDT stock has failed to gain traction since 2020. However, that didn't stop two Congressional representatives from making a total of three purchases of the stock in January 2024.
Medtronic makes the bulk of its revenue in cardiovascular, neuroscience, and medical-surgical segments. All three segments will show strong growth in the next 10 years. That growth doesn't appear to be factored into MDT stock, which is up just 0.81% in the last 12 months, with much of that growth occurring since November 2023.
The Medtronic analyst ratings on MarketBeat give MDT stock a consensus Hold rating with a price target of $94.91, a 13.8% gain from its current price. The company is also one of the top dividend aristocrats, with a dividend yield of 3.31% as of February 29, 2024.
About Medtronic
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.
Read More - Current Price
- $82.73
- Consensus Rating
- Hold
- Ratings Breakdown
- 7 Buy Ratings, 9 Hold Ratings, 1 Sell Ratings.
- Consensus Price Target
- $95.00 (14.8% Upside)
